Novel formulation of a reconstituted high-density lipoprotein (CSL112) dramatically enhances ABCA1-dependent cholesterol efflux

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 33, Issue 9, 2013, Pages 2202-2211

  Diditchenko, Svetlana ^a   Gille, Andreas ^b   Pragst, Ingo ^c   Stadler, Dominik ^a   Waelchli, Marcel ^a   Hamilton, Ross ^b   Leis, Andrew ^d   Wright, Samuel D ^e  

^a CSL Behring AG   (Switzerland)

^b CSL LIMITED   (Australia)

^c CSL BEHRING GMBH   (Germany)

^d CSIRO   (Australia)

^e CSL BEHRING   (United States)

Author keywords

acute coronary syndrome; apolipoproteins; cholesterol; high density lipoproteins, pre ; inflammation

Indexed keywords

ABC TRANSPORTER A1; APOLIPOPROTEIN A1; CHOLESTEROL; CSL 112; HIGH DENSITY LIPOPROTEIN; INTERCELLULAR ADHESION MOLECULE 1; UNCLASSIFIED DRUG;

ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL ESTERIFICATION; CYTOKINE RELEASE; DRUG FORMULATION; HUMAN; INFLAMMATION; MACROPHAGE; NONHUMAN; PRIORITY JOURNAL; RABBIT;

ACUTE CORONARY SYNDROME; APOLIPOPROTEINS; CHOLESTEROL; HIGH-DENSITY LIPOPROTEINS, PRE-Β; INFLAMMATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTICHOLESTEREMIC AGENTS; APOLIPOPROTEIN A-I; ATP-BINDING CASSETTE TRANSPORTERS; BIOLOGICAL TRANSPORT; CELL LINE; CHOLESTEROL; CHOLESTEROL ESTERS; CHOLESTEROL, HDL; CYTOKINES; FEMALE; HUMANS; INFLAMMATION MEDIATORS; INFUSIONS, INTRAVENOUS; LIPOPROTEINS, HDL; MACROPHAGES; MICE; PARTICLE SIZE; RABBITS; UP-REGULATION;

EID: 84883296765     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.113.301981     Document Type: Article

References (35)

1. Cornel JH, Becker RC, Goodman SG, Husted S, Katus H, Santoso A, Steg G, Storey RF, Vintila M, Sun JL, Horrow J, Wallentin L, Harrington R, James S. Prior smoking status, clinical outcomes, and the comparison of ticagrelor with clopidogrel in acute coronary syndromes-insights from the PLATelet inhibition and patient Outcomes (PLATO) trial. Am Heart J. 2012;164:334-342.e1.
2. Rosenson RS, Brewer HB Jr, Davidson WS, Fayad ZA, Fuster V, Goldstein J, Hellerstein M, Jiang XC, Phillips MC, Rader DJ, Remaley AT, Rothblat GH, Tall AR, Yvan-Charvet L. Cholesterol efflux and atheroprotection: advancing the concept of reverse cholesterol transport. Circulation. 2012;125:1905-1919.
3. Williams KJ, Feig JE, Fisher EA. Rapid regression of atherosclerosis: insights from the clinical and experimental literature. Nat Clin Pract Cardiovasc Med. 2008;5:91-102. (Pubitemid 351168064)
4. Sankaranarayanan S, de la Llera-Moya M, Drazul-Schrader D, Asztalos BF, Weibel GL, Rothblat GH. Importance of macrophage cholesterol content on the flux of cholesterol mass. J Lipid Res. 2010;51:3243-3249.
5. Potteaux S, Gautier EL, Hutchison SB, van Rooijen N, Rader DJ, Thomas MJ, Sorci-Thomas MG, Randolph GJ. Suppressed monocyte recruitment drives macrophage removal from atherosclerotic plaques of Apoe-/-mice during disease regression. J Clin Invest. 2011;121:2025-2036.
6. Feig JE, Rong JX, Shamir R, Sanson M, Vengrenyuk Y, Liu J, Rayner K, Moore K, Garabedian M, Fisher EA. HDL promotes rapid atherosclerosis regression in mice and alters inflammatory properties of plaque monocytederived cells. Proc Natl Acad Sci USA. 2011;108:7166-7171.
7. Cimmino G, Ibanez B, Vilahur G, Speidl WS, Fuster V, Badimon L, Badimon JJ. Up-regulation of reverse cholesterol transport key players and rescue from global inflammation by ApoA-I(Milano). J Cell Mol Med. 2009;13(9B):3226-3235.
8. Shaw JA, Bobik A, Murphy A, Kanellakis P, Blombery P, Mukhamedova N, Woollard K, Lyon S, Sviridov D, Dart AM. Infusion of reconstituted high-density lipoprotein leads to acute changes in human atherosclerotic plaque. Circ Res. 2008;103:1084-1091.
9. Degoma EM, Rader DJ. Novel HDL-directed pharmacotherapeutic strategies. Nat Rev Cardiol. 2011;8:266-277.
10. Tardif JC, Heinonen T, Noble S. High-density lipoprotein/apolipoprotein A-I infusion therapy. Curr Atheroscler Rep. 2009;11:58-63.
11. Oram JF. HDL apolipoproteins and ABCA1: partners in the removal of excess cellular cholesterol. Arterioscler Thromb Vasc Biol. 2003;23:720-727. (Pubitemid 36566158)
12. Puig O, Yuan J, Stepaniants S, et al. A gene expression signature that classifies human atherosclerotic plaque by relative inflammation status. Circ Cardiovasc Genet. 2011;4:595-604.
13. Rosenson RS, Brewer HB Jr, Chapman MJ, Fazio S, Hussain MM, Kontush A, Krauss RM, Otvos JD, Remaley AT, Schaefer EJ. HDL measures, particle heterogeneity, proposed nomenclature, and relation to atherosclerotic cardiovascular events. Clin Chem. 2011;57:392-410.
14. Nanjee MN, Crouse JR, King JM, Hovorka R, Rees SE, Carson ER, Morgenthaler JJ, Lerch P, Miller NE. Effects of intravenous infusion of lipid-free apoA-I in humans. Arterioscler Thromb Vasc Biol. 1996;16:1203-1214. (Pubitemid 26299295)
15. Nanjee MN, Doran JE, Lerch PG, Miller NE. Acute effects of intravenous infusion of ApoA1/phosphatidylcholine discs on plasma lipoproteins in humans. Arterioscler Thromb Vasc Biol. 1999;19:979-989. (Pubitemid 29177346)
16. Gogonea V, Gerstenecker GS, Wu Z, Lee X, Topbas C, Wagner MA, Tallant TC, Smith JD, Callow P, Pipich V, Malet H, Schoehn G, DiDonato JA, Hazen SL. The low-resolution structure of nHDL reconstituted with DMPC with and without cholesterol reveals a mechanism for particle expansion. J Lipid Res. 2013;54:966-983.
17. Chetty PS, Nguyen D, Nickel M, Lund-Katz S, Mayne L, Englander SW, Phillips MC. Comparison of apoA-I helical structure and stability in discoidal and spherical HDL particles by HX and mass spectrometry. J Lipid Res. 2013;54:1589-1597.
18. Mackinnon M, Savage J, Wishart R, Barter P. Metabolism of high density lipoproteins by the perfused rabbit liver. J Biol Chem. 1986;261:2548-2552. (Pubitemid 17218262)
19. Favari E, Calabresi L, Adorni MP, Jessup W, Simonelli S, Franceschini G, Bernini F. Small discoidal pre-beta1 HDL particles are efficient acceptors of cell cholesterol via ABCA1 and ABCG1. Biochemistry. 2009;48:11067-11074.
20. Waksman R, Torguson R, Kent KM, Pichard AD, Suddath WO, Satler LF, Martin BD, Perlman TJ, Maltais JA, Weissman NJ, Fitzgerald PJ, Brewer HB Jr. A first-in-man, randomized, placebo-controlled study to evaluate the safety and feasibility of autologous delipidated high-density lipoprotein plasma infusions in patients with acute coronary syndrome. J Am Coll Cardiol. 2010;55:2727-2735.
21. Sacks FM, Rudel LL, Conner A, Akeefe H, Kostner G, Baki T, Rothblat G, de la Llera-Moya M, Asztalos B, Perlman T, Zheng C, Alaupovic P, Maltais JA, Brewer HB. Selective delipidation of plasma HDL enhances reverse cholesterol transport in vivo. J Lipid Res. 2009;50:894-907.
22. Chen W, Silver DL, Smith JD, Tall AR. Scavenger receptor-BI inhibits ATP-binding cassette transporter 1-mediated cholesterol efflux in macrophages. J Biol Chem. 2000;275:30794-30800.
23. Czarnecka H, Yokoyama S. Regulation of cellular cholesterol efflux by lecithin:cholesterol acyltransferase reaction through nonspecific lipid exchange. J Biol Chem. 1996;271:2023-2028. (Pubitemid 26047786)
24. Chen Z, O'Neill EA, Meurer RD, et al. Reconstituted HDL elicits marked changes in plasma lipids following single-dose injection in C57Bl/6 mice. J Cardiovasc Pharmacol Ther. 2012;17:315-323.
25. Sgoutas DS. Fatty acid specificity of plasma phosphatidylcholine: cholesterol acyltransferase. Biochemistry. 1972;11:293-296.
26. Kosek AB, Durbin D, Jonas A. Binding affinity and reactivity of lecithin cholesterol acyltransferase with native lipoproteins. Biochem Biophys Res Commun. 1999;258:548-551. (Pubitemid 29290305)
27. Yvan-Charvet L, Kling J, Pagler T, Li H, Hubbard B, Fisher T, Sparrow CP, Taggart AK, Tall AR. Cholesterol efflux potential and antiinflammatory properties of high-density lipoprotein after treatment with niacin or anacetrapib. Arterioscler Thromb Vasc Biol. 2010;30:1430-1438.
28. Fessler MB, Parks JS. Intracellular lipid flux and membrane microdomains as organizing principles in inflammatory cell signaling. J Immunol. 2011;187:1529-1535.
29. Murphy AJ, Woollard KJ, Hoang A, Mukhamedova N, Stirzaker RA, McCormick SP, Remaley AT, Sviridov D, Chin-Dusting J. High-density lipoprotein reduces the human monocyte inflammatory response. Arterioscler Thromb Vasc Biol. 2008;28:2071-2077.
30. Murphy AJ, Westerterp M, Yvan-Charvet L, Tall AR. Anti-atherogenic mechanisms of high density lipoprotein: effects on myeloid cells. Biochim Biophys Acta. 2012;1821:513-521.
31. Libby P. Inflammation in atherosclerosis. Nature. 2002;420:868-874. (Pubitemid 36019640)
32. Nichols AV, Blanche PJ, Gong EL, Shore VG, Forte TM. Molecular pathways in the transformation of model discoidal lipoprotein complexes induced by lecithin:cholesterol acyltransferase. Biochim Biophys Acta. 1985;834:285-300. (Pubitemid 15025236)
33. Liang HQ, Rye KA, Barter PJ. Remodelling of reconstituted high density lipoproteins by lecithin: cholesterol acyltransferase. J Lipid Res. 1996;37:1962-1970.
34. Clay MA, Hopkins GJ, Ehnholm CP, Barter PJ. The rabbit as an animal model of hepatic lipase deficiency. Biochim Biophys Acta. 1989;1002:173-181. (Pubitemid 19090941)
35. Khera AV, Cuchel M, de la Llera-Moya M, Rodrigues A, Burke MF, Jafri K, French BC, Phillips JA, Mucksavage ML, Wilensky RL, Mohler ER, Rothblat GH, Rader DJ. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med. 2011;364:127-135.